Prognostic Value of TRPM7 Expression and Factor XIIIa-Expressing Tumor-Associated Macrophages in Gastric Cancer

Table 1

Basic clinicopathological characteristics of the patients and the effects of these parameters on overall survival (univariate analysis).

Parameters	(%)		Overall survival
			HR (95% CI)	value
Gender
Male	126 (61.8%)		1.02 (0.75–1.40)	0.862
Female	78 (38.2%)
Age
≤60 year	74 (36.3%)		1.01 (0.73–1.39)	0.939
>60 year	30 (63.7%)
Size
≤5 cm	79 (38.7%)		1.35 (0.98–1.85)	0.060
>5 cm	125 (61.3%)
Site
Proximal	47 (23.0%)		0.43 (0.27–0.69)	<0.001
Middle	63 (30.9%)
Distal	54 (26.5%)
Diffuse	40 (19.6%)
Borrmann
Type 1	28 (13.7%)		1.33 (0.81–2.18)	0.254
Type 2	60 (29.4%)
Type 3	76 (37.3%)
Type 4	40 (19.6%)
Lauren
Intestinal	155 (76.0%)		1.47 (0.98–2.20)	0.057
Diffuse	33 (16.2%)
Indeterminate	16 (7.8%)
Histopathological type
Adenocarcinoma-NOS	110 (53.9%)		0.90 (0.76–1.08)	0.275
Mucinous	50 (24.5%)
Signet ring cell	32 (15.7%)
Poorly cohesive	12 (5.9%)
Histologic grade
Grade 1	24 (11.8%)		2.74 (1.48–5.09)	0.001
Grade 2	124 (60.8%)
Grade 3	56 (27.5%)
Goseki grade
Grade 1	73 (35.8%)		0.95 (0.84–1.07)	0.430
Grade 2	23 (11.3%)
Grade 3	44 (21.6%)
Grade 4	64 (31.4%)
Lymphovascular invasion
Absent	74 (36.3%)		1.45 (1.04–2.00)	0.022
Present	130 (63.7%)
Perineural invasion
Absent	90 (44.1%)		1.12 (0.81–1.54)	0.465
Present	114 (55.9%)
Depth of invasion
pT1	12 (5.9%)		2.62 (2.07–3.32)	<0.001
pT2	24 (11.8%)
pT3	112 (54.9%)
pT4	56 (27.5)
Lymph node metastasis
Absent	25 (12.3%)		2.18 (1.83–2.59)	<0.001
1–2	44 (21.6%)
3–6	62 (30.4%)
≥7	73 (35.8%)
Distant metastasis
Absent	132 (64.7%)		5.65 (4.04–7.89)	<0.001
Present	72 (35.3%)
TNM stage
I	20 (9.8%)		4.09 (3.26–5.12)	<0.001
II	48 (23.5%)
III	76 (37.3%)
IV	60 (29.4%)

SD: standard deviation; HR: hazard ratio; CI: confidence interval.